Goldman Sachs
EGRX

Goldman Sachs’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

Goldman Sachs’s Portfolio EGRX Stock Details EGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-2,100
Closed -$112K – 6476
2017
Q4 		$112K Sell
2,100
-100
-5% -$5.57K ﹤0.01% 5704
2017
Q3 		$131K Sell
2,200
-1,200
-35% -$72.6K ﹤0.01% 5959
2017
Q2 		$268K Sell
3,400
-3,200
-48% -$262K ﹤0.01% 5598
2017
Q1 		$547K Buy
6,600
+6,400
+3,200% +$476K ﹤0.01% 4945
2016
Q4 		$16K Sell
200
-1,400
-88% -$102K ﹤0.01% 6696
2016
Q3 		$112K Sell
1,600
-9,600
-86% -$532K ﹤0.01% 6174
2016
Q2 		$434K Sell
11,200
-29,300
-72% -$1.22M ﹤0.01% 4980
2016
Q1 		$1.64M Buy
40,500
+9,100
+29% +$577K ﹤0.01% 3664
2015
Q4 		$2.78M Buy
31,400
+29,200
+1,327% +$2.31M ﹤0.01% 3344
2015
Q3 		$163K Buy
+2,200
New +$183K ﹤0.01% 6143

Other funds holding EGRX

XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
Simplex Trading
Simplex Trading Chicago, Illinois $149B AUM 62.07% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
SLG
Stanley-Laman Group Berwyn, Pennsylvania $814M AUM 40.24% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return
AIC
Archer Investment Corporation Carmel, Indiana $469M AUM 19.1% 1-Year Est. Return
Credit Agricole
Credit Agricole Montrouge Cedex, France $38.1B AUM
FFA
Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return

Goldman Sachs's EGRX Position: Q4 2024 in Review

Goldman Sachs sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q4 2024, closing a stake of 31,495 shares — an estimated $117K sold.

Goldman Sachs first reported a position in EGRX in Q1 2015 and held it in 39 quarters. The position peaked at $15.1M in Q1 2020. 9 funds tracked by Wall St. Rank hold EGRX as of Q4 2024.

  • Goldman Sachs reported no remaining Eagle Pharmaceuticals, Inc. position as of Q4 2024 after selling out during the quarter.
  • Goldman Sachs sold 31,495 Eagle Pharmaceuticals, Inc. shares in Q4 2024, an estimated $117K.
  • Goldman Sachs first reported a position in Eagle Pharmaceuticals, Inc. in Q1 2015 and held it in 39 quarters.
  • Goldman Sachs's Eagle Pharmaceuticals, Inc. position peaked at $15.1M in Q1 2020.
  • 9 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q4 2024.

Based on Goldman Sachs's 13F filing for Q4 2024, filed 11 Feb 2025.